Cardiff Oncology, Inc. · NASDAQ:CRDF

Cardiff Oncology, Inc. financial statements

Cardiff Oncology, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue593.0K683.0K488.0K386.0K359.0K366.0K244.6K378.3K505.4K381.1K
Cost of revenue904.0K404.0K398.0K200.0K500.0K11.2M0597.5K1.81M1.73M
Gross profit593.0K683.0K488.0K386.0K359.0K366.0K244.6K-219.0K-1.31M-1.35M
Research and development35.3M36.9M32.9M27.1M17.4M11.2M11.2M8.16M7.88M15.0M
Selling, general and administrative14.2M12.5M13.0M13.2M11.8M8.22M5.76M8.01M14.2M11.5M
Operating income-49.0M-48.7M-45.4M-39.9M-28.9M-19.1M-16.7M-17.1M-25.6M-40.1M
Depreciation and amortization364.0K404.0K398.0K236.0K451.0K466.0K494.2K859.5K1.25M1.07M
EBITDA-48.6M-48.2M-45.0M-39.7M-28.4M-18.6M-16.2M-16.2M-24.3M-39.1M
Interest expense1.58M02.00K025.4K1.03M1.67M
Income before tax-45.9M-45.4M-41.4M-38.7M-28.3M-19.3M-16.4M-16.5M-24.9M-39.2M
Income tax0000000000
Net income-45.9M-45.4M-41.4M-38.7M-28.3M-19.3M-16.4M-16.5M-24.9M-39.2M
Earnings per share, basic-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26-51.76-1.30
Earnings per share, diluted-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26-51.76-1.37

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents17.5M51.5M21.7M16.3M11.9M131.0M10.2M11.5M8.23M13.9M
Short-term investments40.8M40.3M53.2M88.9M128.9M0024.0M
Receivables182.0K773.0K288.0K771.0K535.0K320.0K203.5K167.8K77.1K100.5K
Inventory11
Current assets60.1M95.1M77.4M111.3M146.1M133.4M11.4M12.8M9.47M39.0M
Property, plant and equipment578.0K898.0K1.24M1.27M382.0K624.0K877.8K1.30M2.43M3.83M
Total assets61.9M97.2M81.6M116.2M149.5M134.7M13.1M14.2M12.3M44.0M
Accounts payable8.09M4.82M1.97M1.96M1.44M1.37M656.3K664.8K825.2K1.13M
Current liabilities16.4M13.4M10.4M7.81M6.56M6.12M4.78M2.92M3.95M7.80M
Long-term debt014.2M
Total debt832.0K1.52M2.15M2.71M3.12M869.0K1.73M01.33M2.36M
Total liabilities16.5M14.2M11.9M9.85M9.13M6.57M5.78M4.09M5.78M24.2M
Shareholders' equity45.4M82.9M69.7M106.3M140.4M128.2M7.31M10.1M6.51M19.8M
Shares outstanding68.3M66.5M44.7M44.7M42.0M36.8M8.59M3.83M733.2K30.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-37.9M-37.7M-30.9M-33.8M-23.0M-16.3M-13.3M-13.2M-23.3M-31.0M
Capital spending-44.0K-80.0K-582.0K-1.01M-205.0K-211.0K-67.6K-5.10K-101.1K-823.5K
Free cash flow-38.0M-37.8M-31.5M-34.8M-23.2M-16.5M-13.3M-13.2M-23.4M-31.9M
Cash from investing1.34M13.7M36.2M38.1M-131.4M-211.0K-67.6K22.8K24.0M-24.8M
Cash from financing2.58M53.8M075.0K35.5M137.3M12.1M16.4M-6.38M2.30M
Dividends paid-414.0K-24.0K-24.2M-24.2M-24.2M-24.2M-24.2M
Share buybacks75.0K35.5M24.2M12.1M32.1M25.1M24.2M
Change in cash-34.0M29.8M5.31M4.40M-119.0M120.8M-1.26M3.23M-5.69M-53.6M